Organisation paid for research Program year 2025 Source: CMS Open Payments

Barrow Neurological Institute

Neither a doctor nor a teaching hospital

Research payments

$510,949

62 payments

Through program year 2025, Barrow Neurological Institute is reported as receiving $510,949 in research payments, across 62 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $92,657 4
2024 Research $105,148 6
2023 Research $271,767 28
2022 Research $14,534 12
2021 Research $12,229 3
2020 Research $2,127 4
2019 Research $12,489 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $449,471 4 payments
  2. Biogen, Inc. $13,824 7 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $11,334 1 payment
  4. Biohaven Pharmaceuticals, Inc. $11,297 2 payments
  5. Amylyx Pharmaceuticals, Inc. $10,984 6 payments
  6. H. Lundbeck A S $7,403 12 payments
  7. Mitsubishi Tanabe Pharma America, Inc. $2,500 1 payment
  8. Ares Trading SA $1,020 13 payments
  9. AbbVie, Inc. $932 1 payment
  10. Boston Scientific Corporation $792 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Intact Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration $449,471 4 payments
  2. A Seamless Phase 2A-B Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimers Disease $11,334 1 payment
  3. A Seamless Phase 2A-B Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimers Disease $11,297 2 payments
  4. Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) $10,984 6 payments
  5. Eptinezumab in Participants With Episodic Cluster Headache (Alleviate) $7,403 12 payments
  6. An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) $5,266 2 payments
  7. Methodology Study of Novel Outcome Measures to Assess Progression of ALS $3,940 1 payment
  8. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis $2,978 1 payment
  9. Radicava (Edavarone) Findings in Biomarkers From Als (Refine-Als) $2,500 1 payment
  10. Long-Term Evaluation of BIIB067 $1,425 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record